Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 3,917 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertension Clear all

Conditions: Hypertension
Interventions: Partial sleep deprivation (sleep restriction), Normal sleep; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 35 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hypertension
Interventions: Computerized reminders about treatment guidelines to providers who care for hypertensive patients; Behavioral
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 20 Years and older
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Diseases, Heart Diseases, Hypertension
Interventions: Patient-centered Counseling; Behavioral
Lead sponsor: Boston Medical Center; Other
Eligibility: 21 Years to 100 Years
Enrollment: 870 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertensive Disorders of Pregnancy, Chronic Hypertension in Pregnancy, Gestational Hypertension
Interventions: Community Health Worker (CHW)/Social Worker (SW)-led non-medical health related needs (NMHRN) intervention + Clinician-Led Medication Therapy Management (MTM) with remote blood pressure monitoring, Active Comparator (Control group); Behavioral
Lead sponsor: Texas Southern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: Coenzyme Q-10 in Pulmonary Hypertension subjects, Coenzyme Q-10 in Normal Control subjects; Dietary Supplement
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Pulmonary Hypertension of Newborn
Interventions: INOmax; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 27 Weeks to 40 Weeks
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 30
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more

Conditions: Hypertension
Interventions: 6 weeks of exercise training (Pre-training), 6 weeks of exercise training (Post-training); Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Glaucoma, Ocular Hypertension
Interventions: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution, Concurrent brimonidine 0.2% and 0.5% timolol; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Hypertension
Interventions: Position of arm while taking blood pressure measurement; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cataract, Age-related Cataract, Circadian Rhythm Disorders, Glaucoma, Age Related Macular Degeneration
Interventions: Blue-light filtering intraocular lens, Conventional intraocular lens; Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years and older
Enrollment: 10,192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: Communication with basic table, Communication with enhanced table, Communication with enhanced graph; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 542 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Refractory Hypertension
Interventions: Reserpine; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertension (Without Type 2 Diabetes Mellitus), High Blood Pressure, Male, Female, Adult, Cognition, Endothelial Function (Reactive Hyperemia), Oxidative Stress, Diet, Overweight, Body Composition Measurement, Gut Microbiome, Arterial Stiffness, Caucasian Whites, Inflammation, Microvascular Function
Interventions: Wild Blueberry, Placebo; Dietary Supplement
Lead sponsor: Georgia State University; Other
Eligibility: 45 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprostene bunod; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 20 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Hypertension, Vascular Stiffness
Interventions: Extra Virgin Olive Oil, Control Oil; Dietary Supplement
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Diastolic Heart Failure, Hypertensive Heart Disease
Interventions: DASH/sodium-restricted diet (DASH/SRD), Control Diet; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 50 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Glaucoma
Interventions: magnetic resonance imaging (MRI) of the brain; Diagnostic Test
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 65 Years and older
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pulmonary Hypertension
Interventions: sitaxsentan sodium; Drug
Lead sponsor: ICOS-Texas Biotechnology; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 21 more

Conditions: Prehypertension
Interventions: Labeled prehypertension, Unlabeled prehypertension; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions: Pulmonary endarterectomy, Balloon pulmonary angioplasty, Pulmonary hypertension (PH)-specific medication; Procedure · Drug
Lead sponsor: International CTEPH Association; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: San Diego, California • Evanston, Illinois • Durham, North Carolina + 1 more

Conditions: Hypertension, Prehypertension, Overweight, Obesity, Hypertrophy, Left Ventricular
Interventions: Electronic Media Application, Standard of care education; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 22 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypertension
Interventions: HCTZ + Amlodipine, Valsartan/HCTZ; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Muscle Shoals, Alabama • Westlake Village, California • Oklahoma City, Oklahoma + 2 more

Search by objective public record fields.

Sleep Restriction and Parental History of Hypertension

Impact of Computerized Reminders on Blood Pressure Documentation and Control

Clinician Counseling and Cultural Competency to Improve Hypertension Control and Therapy Adherence

MH-Rx Study (Baby on Board: Check-in on You, Your Medication, & Your Blood Pressure)

Coenzyme Q-10 and Pulmonary Arterial Hypertension

Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension

AM vs PM Exercise Training

Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients

ARMS: The Arm Rest and Support Study

Association Between Light Spectrum and Survival After Cataract Surgery

Helping Hypertension Patients to Interpret Blood Pressure Readings and Motivate Blood Pressure Control

Mechanisms of Refractory Hypertension (Reserpine)

Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT

Cardiovascular Effects of EVOO in Healthy Reproductive-aged Women

Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)

Does Glaucoma Cause Loss of Brain Function?

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension

Prehypertension Labeling

TrEatment Approach in the Multimodal Era Registry

EMPower: Electronic Media Powering Positive Health Changes in Youth

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults